About: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $26.86 (+5.91%)
VKTX NASDAQ Viking Therapeutics Inc
Viking Therapeutics Inc share price
Atividade de preço de VKTX
Último preço
$ 26,860
Variação (24h)
1,50 USD (5,91%)
Volume
6.74M
Volume (média 4 sem.)
-
Abertura
$ 24,38
Variação do dia
$ 24,38 - $ 27,76
Fechamento anterior
$ 25,36
Último negócio
29 Oct, 8:28 pm GMT+0
Atrasado
29 Oct, 8:28 pm GMT+0
VKTX price performance
Atrasado
29 Oct, 8:28 pm GMT+0
quote.marketSignals